AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer
ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal...